Skip to main content
Article thumbnail
Location of Repository

Molecular Diagnostic and Pathogenesis of Hereditary Hemochromatosis

By Paulo C. J. L. Santos, Jose E. Krieger and Alexandre C. Pereira


Hereditary hemochromatosis (HH) is an autosomal recessive disorder characterized by enhanced intestinal absorption of dietary iron. Without therapeutic intervention, iron overload leads to multiple organ damage such as liver cirrhosis, cardiomyopathy, diabetes, arthritis, hypogonadism and skin pigmentation. Most HH patients carry HFE mutant genotypes: homozygosity for p.Cys282Tyr or p.Cys282Tyr/p.His63Asp compound heterozygosity. In addition to HFE gene, mutations in the genes that encode hemojuvelin (HJV), hepcidin (HAMP), transferrin receptor 2 (TFR2) and ferroportin (SLC40A1) have been associated with regulation of iron homeostasis and development of HH. The aim of this review was to identify the main gene mutations involved in the pathogenesis of type 1, 2, 3 and 4 HH and their genetic testing indication. HFE testing for the two main mutations (p.Cys282Tyr and p.His63Asp) should be performed in all patients with primary iron overload and unexplained increased transferrin saturation and/or serum ferritin values. The evaluation of the HJV p.Gly320Val mutation must be the molecular test of choice in suspected patients with juvenile hemochromatosis with less than 30 years and cardiac or endocrine manifestations. In conclusion, HH is an example that genetic testing can, in addition to performing the differential diagnostic with secondary iron overload, lead to more adequate and faster treatment

Topics: Review
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2005). A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: Hyperferritinemia associated with a relatively low transferrin saturation of iron.
    2. (2005). A mouse model of juvenile hemochromatosis.
    3. (2000). A novel mammalian iron-regulated protein involved in intracellular iron metabolism.
    4. (2010). A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology
    5. (2005). A Portuguese patient homozygous for the -25G>A mutation of the HAMP promoter shows evidence of steady-state transcription but fails to up-regulate hepcidin levels by iron. Blood
    6. (2005). A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab.
    7. (2004). Absence of hemochromatosis associated Cys282Tyr HFE gene mutation and low frequency of hemochromatosis phenotype in nonalcoholic chronic liver disease patients in
    8. (2011). Advantage of high-resolution melting curve analysis over conformation-sensitive gel electrophoresis for mutational screening of BRCA1 and BRCA2 genes.
    9. (2008). An unusual case of hemochromatosis due to a new compound heterozygosity in HFE (p.[Gly43Asp;His63Asp]+[Cys282Tyr]): Structural implications with respect to binding with transferrin receptor 1.
    10. (2001). An unusual melting curve profile in LightCycler multiplex genotyping of the hemochromatosis H63D/C282Y gene mutations.
    11. (2009). BMP/Smad signaling is not enhanced in Hfe-deficient mice despite increased Bmp6 expression. Blood
    12. (2009). BMP6 is a key endogenous regulator of hepcidin expression and iron
    13. (2009). Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD.
    14. (2006). Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression.
    15. (2009). Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis. Gastroenterology
    16. (2005). Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood
    17. (2000). Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor.
    18. (2008). Current approach to hemochromatosis. Blood Rev.
    19. (2006). Current approaches to the management of hemochromatosis.
    20. (2002). Decreased liver hepcidin expression in the Hfe knockout mouse. Blood Cells Mol. Dis.
    21. (2011). Diagnosis and management of hereditary haemochromatosis.
    22. (2003). Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet
    23. (2010). EASL clinical practice guidelines for HFE hemochromatosis.
    24. (2005). Effect of ferroportin Q248H polymorphism on iron status in African children.
    25. (2010). Ferroportin disease: A systematic meta-analysis of clinical and molecular
    26. (2005). First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut
    27. (2004). Genetic abnormalities and juvenile hemochromatosis: Mutations of the HJV gene encoding hemojuvelin. Blood
    28. (2005). Genetic and clinical heterogeneity of ferroportin disease.
    29. (2012). genetic profile of hereditary hemochromatosis in Russians: High frequency of C282Y mutation in population, but not in patients. Blood Cells Mol. Dis.
    30. Genotyping of the hemochromatosis HFE p.H63D and p.C282Y mutations by high-resolution melting with the Rotor-Gene 6000((R)) instrument.
    31. (1997). Global prevalence of putative haemochromatosis mutations.
    32. (2004). HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood
    33. (2001). Hemochromatosis: Diagnosis and management. Gastroenterology
    34. (2006). Hemochromatosis: Genetics and pathophysiology.
    35. Hemojuvelin and hepcidin genes sequencing in Brazilian patients with primary iron overload.
    36. (2005). Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload.
    37. (2009). Hemojuvelin: The hepcidin story continues.
    38. Hepcidin in human iron disorders: Therapeutic implications.
    39. (2005). Hepcidin in iron overload disorders. Blood
    40. (2005). Hepcidin is decreased in TFR2 hemochromatosis. Blood
    41. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science
    42. (2006). Hereditary hemochromatosis: Genetic complexity and new diagnostic approaches.
    43. (2011). Hereditary hemochromatosis: Laboratory evaluation.
    44. (2010). Hereditary hemochromatosis: Mutations in genes involved in iron homeostasis in Brazilian patients. Blood Cells Mol. Dis.
    45. (2010). Hereditary hemochromatosis: Pathogenesis, diagnosis, and treatment. Gastroenterology
    46. (2008). HFE association with transferrin receptor 2 increases cellular uptake of transferrin-bound iron.
    47. HFE gene mutations and iron status of Brazilian blood donors.
    48. (2010). HFE gene mutations in patients with primary iron overload: Is there a significant improvement in molecular diagnosis yield with HFE sequencing? Blood Cells Mol. Dis.
    49. (2007). HFE modulates transferrin receptor 2 levels in hepatoma cells via interactions that differ from transferrin receptor 1-HFE interactions.
    50. (2009). HFE-associated hereditary hemochromatosis.
    51. (2011). High resolution melting analysis for the detection of SLC25A13 gene mutations in Taiwan.
    52. High resolution melting for the identification of mutations in the iron responsive element of the ferritin light chain gene.
    53. (2005). HJV gene mutations in European patients with juvenile hemochromatosis.
    54. (2010). HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: Treatment with phlebotomy and deferasirox. Acta Haematol.
    55. (2009). Homozygous deletion of HFE: The Sardinian hemochromatosis? Blood
    56. (2006). Homozygous p.M172K mutation of the TFR2 gene in an Italian family with type 3 hereditary hemochromatosis and early onset iron overload. Haematologica
    57. (2004). Identification of new mutations of hepcidin and hemojuvelin in patients with HFE C282Y allele. Blood Cells Mol. Dis.
    58. (2005). In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood
    59. (2009). Iron deficiency and frequency of HFE C282Y gene mutation in Brazilian blood donors.
    60. (2011). Iron regulation of hepcidin despite attenuated smad1,5,8 signaling in mice without transferrin receptor 2 or hfe. Gastroenterology
    61. (2007). Juvenile hemochromatosis caused by a novel combination of hemojuvelin G320V/R176C mutations in a 5-year old girl. Haematologica
    62. (2009). Lack of the bone morphogenetic protein BMP6 induces massive iron
    63. (2007). Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance.
    64. (2003). Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood
    65. (1999). Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family.
    66. (2006). Molecular insights into the pathogenesis of hereditary haemochromatosis. Gut
    67. (2003). Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.
    68. (2009). Mutations in HAMP and HJV genes and their impact on expression of clinical hemochromatosis in a cohort of 100 Spanish patients homozygous for the C282Y mutation of HFE
    69. (2000). Nonexpressing homozygotes for C282Y hemochromatosis: Minority or majority of cases?
    70. (2003). Phenotypic expression of the C282Y/Q283P compound heterozygosity in HFE and molecular modeling of the Q283P mutation effect. Blood Cells Mol. Dis.
    71. (2009). Rare types of genetic hemochromatosis. Acta Haematol.
    72. Regulation of hepcidin and iron-overload disease.
    73. (2004). Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood
    74. (2002). Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis.
    75. (2004). The clinical relevance of new insights in iron transport
    76. (2005). The evaluation of hyperferritinemia: An updated strategy based on advances in detecting genetic abnormalities.
    77. (2000). The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22.
    78. The molecular basis of iron overload disorders and iron-linked anemias.
    79. (2009). The role of hepcidin in iron metabolism. Acta Haematol.
    80. (2008). The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.